PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China · Delayed Price · Currency is CNY 41.14
+0.99 (2.47%)
Feb 3, 2026, 3:04 PM CST
SHE:300725 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,977 | 1,686 | 1,725 | 1,594 | 1,201 | 1,022 |
Other Revenue | 3.09 | 3.09 | 0.45 | 0.49 | 0.36 | 0.13 |
| 1,980 | 1,689 | 1,725 | 1,595 | 1,202 | 1,022 | |
Revenue Growth (YoY) | 26.78% | -2.12% | 8.18% | 32.71% | 17.55% | 54.36% |
Cost of Revenue | 1,406 | 1,106 | 1,018 | 878.71 | 632.85 | 556.44 |
Gross Profit | 573.89 | 582.74 | 707.2 | 715.99 | 568.78 | 465.79 |
Selling, General & Admin | 233 | 238.47 | 253.44 | 248.49 | 174.63 | 151.83 |
Research & Development | 97.41 | 107.33 | 169.17 | 168.32 | 114.02 | 90.93 |
Other Operating Expenses | -1.72 | 6.4 | 14.8 | 11.89 | 8.28 | 6.37 |
Operating Expenses | 328.67 | 356.1 | 447.24 | 435.78 | 299.34 | 253.98 |
Operating Income | 245.23 | 226.64 | 259.95 | 280.21 | 269.44 | 211.81 |
Interest Expense | -50.8 | -60.91 | -66.1 | -45.72 | -9.18 | -0.63 |
Interest & Investment Income | 40.52 | 45.76 | 24.79 | 26.7 | 249.42 | 6.67 |
Currency Exchange Gain (Loss) | 23.65 | 23.65 | 0.46 | 34.45 | -16.92 | -23.64 |
Other Non Operating Income (Expenses) | -11.74 | -2.96 | 4.58 | -0.92 | 13.47 | -0.08 |
EBT Excluding Unusual Items | 246.86 | 232.19 | 223.69 | 294.72 | 506.23 | 194.13 |
Impairment of Goodwill | -0.44 | -0.44 | - | - | - | - |
Gain (Loss) on Sale of Investments | -0.34 | 9.36 | -21.33 | 1.99 | 1.67 | - |
Gain (Loss) on Sale of Assets | - | - | 0.42 | - | 0.04 | - |
Asset Writedown | -25.7 | -0.96 | -14.8 | -4.38 | -0.17 | -0.18 |
Other Unusual Items | 8.75 | 8.75 | 33.4 | 30.94 | - | 10.56 |
Pretax Income | 229.13 | 248.9 | 221.38 | 323.26 | 507.77 | 204.5 |
Income Tax Expense | 27.99 | 29.36 | 24.01 | -2.63 | 4 | 20.3 |
Earnings From Continuing Operations | 201.14 | 219.54 | 197.36 | 325.89 | 503.77 | 184.2 |
Minority Interest in Earnings | - | - | 0 | -11.67 | -17.21 | 0 |
Net Income | 201.14 | 219.54 | 197.36 | 314.22 | 486.56 | 184.21 |
Net Income to Common | 201.14 | 219.54 | 197.36 | 314.22 | 486.56 | 184.21 |
Net Income Growth | 14.87% | 11.24% | -37.19% | -35.42% | 164.14% | 21.13% |
Shares Outstanding (Basic) | 201 | 200 | 199 | 199 | 198 | 186 |
Shares Outstanding (Diluted) | 201 | 200 | 201 | 200 | 199 | 188 |
Shares Change (YoY) | 0.31% | -0.90% | 0.62% | 0.37% | 6.09% | 0.79% |
EPS (Basic) | 1.00 | 1.10 | 0.99 | 1.58 | 2.46 | 0.99 |
EPS (Diluted) | 1.00 | 1.10 | 0.98 | 1.57 | 2.44 | 0.98 |
EPS Growth | 14.51% | 12.25% | -37.58% | -35.66% | 148.98% | 20.19% |
Free Cash Flow | 555 | 184.7 | -68.93 | -311.3 | -267.73 | 196.33 |
Free Cash Flow Per Share | 2.76 | 0.93 | -0.34 | -1.55 | -1.34 | 1.04 |
Dividend Per Share | 0.280 | 0.280 | 0.310 | 0.100 | 0.100 | 0.077 |
Dividend Growth | -9.68% | -9.68% | 210.00% | - | 30.04% | -33.36% |
Gross Margin | 28.99% | 34.51% | 40.99% | 44.90% | 47.33% | 45.57% |
Operating Margin | 12.39% | 13.42% | 15.07% | 17.57% | 22.42% | 20.72% |
Profit Margin | 10.16% | 13.00% | 11.44% | 19.70% | 40.49% | 18.02% |
Free Cash Flow Margin | 28.03% | 10.94% | -4.00% | -19.52% | -22.28% | 19.21% |
EBITDA | 384.84 | 355.41 | 374.25 | 366.45 | 322.64 | 236.28 |
EBITDA Margin | 19.44% | 21.05% | 21.69% | 22.98% | 26.85% | 23.11% |
D&A For EBITDA | 139.62 | 128.77 | 114.3 | 86.24 | 53.2 | 24.47 |
EBIT | 245.23 | 226.64 | 259.95 | 280.21 | 269.44 | 211.81 |
EBIT Margin | 12.39% | 13.42% | 15.07% | 17.57% | 22.42% | 20.72% |
Effective Tax Rate | 12.22% | 11.79% | 10.85% | - | 0.79% | 9.93% |
Revenue as Reported | 1,980 | 1,689 | 1,725 | 1,595 | 1,202 | 1,022 |
Advertising Expenses | - | 1.44 | 1.93 | 0.93 | 0.6 | 0.76 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.